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Cancer patients are often overtreated because of a failure to identify low-risk cancer patients. 
Thus  far,  no  algorithm  has  been  able  to  successfully  generate  cancer  prognostic  gene 
signatures with high accuracy and robustness in order to identify these patients. In this paper, 
we developed an algorithm that identifies prognostic markers using tumour gene microarrays 
focusing  on  metastasis-driving  gene  expression  signals.  Application  of  the  algorithm  to 
breast cancer samples identified prognostic gene signature sets for both estrogen receptor 
(ER) negative (−) and positive (+) subtypes. A combinatorial use of the signatures allowed 
the stratification of patients into low-, intermediate- and high-risk groups in both the training 
set and in eight independent testing sets containing 1,375 samples. The predictive accuracy 
for the low-risk group reached 87–100%. Integrative network analysis identified modules in 
which each module contained the genes of a signature and their direct interacting partners that 
are cancer driver-mutating genes. These modules are recurrent in many breast tumours and 
contribute to metastasis. 
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E
arly detection of various types of cancer before they spread 
would greatly aid clinicians. Prognostic biomarkers may help 
to improve the capacity to predict whether a patient’s cancer is 
going to recur after surgical removal. Traditionally, clinical factors 
such as age and tumour grade have been used to assess prognosis; 
however, they have poor predictive power. As such, poor predic-
tions of cancer recurrence lead to the overtreatment of many cancer 
patients. For example, 70–80% of lymph node-negative breast can-
cer patients may undergo adjuvant chemotherapy when it is, in fact, 
unnecessary1. In addition, almost 60–75% of women with early-
stage breast cancer undergo a toxic therapy from which they will 
not receive any benefit, but instead will experience only side effects2. 
Therefore, it is essential to identify gene markers that are able to 
accurately  identify  low-risk  cancer  patients  who  do  not  require 
adjuvant chemotherapy.
Genome-wide expression profiles that assess the risk of recur-
rence  offer  the  possibility  of  more  precisely  defining  clinical   
outcomes in cancer. Several predictors such as intrinsic-subtype 
classifiers3,  the  recurrence-score  model4,  the  70-gene  signature5, 
the wound-response gene expression signature6 and the ratio of the   
levels of expression of two genes7, which are largely based on an 
unsupervized analysis of breast tumour gene expression profiles 
(‘one-step-clustering’  approach),  have  been  developed  for  breast 
cancer.  However,  these  predictors  have  intermediate  predictive 
power at best (accuracies below 70%)8, and they cannot be used 
across  other  patient  cohorts.  Recently  developed  stromal  gene   
signature9 and network-based gene signatures10,11 showed some level 
of robustness. However, the accuracies of their predictions are still 
lower than 80%. Thus, researchers have struggled to identify robust 
and  highly  accurate  prognostic  biomarkers,  not  only  for  breast 
tumours but also for other types of cancers, during the past decade.
The  ITRANSBIG  Consortium  (http://www.breastinternational 
group.org) suggests that, to be clinically practicable, low-risk patients 
should be associated with 10-year overall survival probabilities of at 
least 88% and 92% for ER +  and ER −  tumours, respectively. Thus 
far, only Oncotype DX, a set of 21 cancer genes, has been shown 
clinically to be able to predict low-risk breast cancer patients with 
such a high degree of accuracy ( > 90%)12. However, Oncotype DX 
is only applicable to one clinical subtype of breast cancer patients 
(that is, Stage I/ER +  tumours). Moreover, the method by which the 
21 genes of the Oncotype DX were generated cannot be applied to 
other breast cancer subtypes or other cancer types.
Through an integrative analysis of a human signalling network 
and the output of the large-scale sequencing of tumour genomes, we 
previously showed that alterations of tumour suppressor genes (for 
example, p53 signalling) are essential in cancer development and 
progression13. Mutation of tumour suppressor genes often increases 
genome instability, which in turn induces genomic alterations such 
as rearrangements, chromosomal fragment amplifications and dele-
tions14. Therefore, tumour cells often have many more ‘passenger 
signals’ than other types of cells, which means that the variability 
of  gene  expression  profiles  between  individual  tumours  can  be 
extremely high, and the ‘real’ cancer gene expression signals may be 
buried in these highly varied profiles. These insights suggest that the 
current marker identification method of the ‘one-step-clustering’ of 
microarray profiles of ‘good’ and ‘bad’ tumours captures numerous 
‘passenger signals’ and renders markers derived from this approach 
less robust and accurate.
On the basis of these insights, we developed a new algorithm: 
Multiple  Survival  Screening  (MSS).  By  applying  MSS  to  breast 
tumours, we discovered six and three marker sets for ER +  and   
ER −  subtypes, respectively. We identified low-risk cancer patients 
with high rates of accuracy (that is, 87–96% and 88–100% in eight 
patient cohorts containing 1,375 samples for good outcomes in 
the  low-risk  groups  of  ER +   and  ER −   subtypes,  respectively). 
Moreover, MSS is applicable to other cancer types and subtypes 
for the identification of prognostic or drug response biomarkers. 
Finally, an integrative network analysis of these gene signatures and 
breast cancer driver-mutating genes in a protein interaction network 
allowed the identification of several metastasis network modules in 
which each module contains the genes of one signature and their 
directly interacting partners that are cancer driver-mutating genes. 
We show that these network modules are repeatedly used in most 
breast tumours by the molecular mechanisms of cancer metastasis.
Results
Most of the multiple prognostic makers are not robust. We have 
demonstrated that those genes the expressions of which are correlated 
with patient survival have a better chance of being associated with 
metastasis (see Supplementary Fig. S1 and Supplementary Methods). 
However,  tumour  heterogeneity  prevents  the  identification  of 
robust cancer biomarkers. It is unknown to what extent tumour 
heterogeneity affects the robustness of gene signatures. To answer 
this question, we carried out a simulation study. We performed   
a genome-wide screening of genes, the expressions of which are 
correlated  with  patient  survival,  by  conducting  survival  analysis 
(referred to as survival screening here) as described previously13, 
for the data sets from the cohorts of Wang et al.15, Chang et al.6 
and van ‘t Veer et al.5 (see Methods). As a result, we obtained three 
gene lists containing 1,755, 3,233 and 1,834 genes, respectively. We   
found  113  genes  that  are  common  among  the  three  gene  lists.   
A total of 49 of the 113 genes are related to cancer hallmarks (that   
is, genes belonging to cancer-related Gene Ontology (GO) terms, 
Table 1). How transferable is a signature derived from one data set 
Table 1 | Selected gene groups used to generate the 1 million random gene sets.
Gene signature NRC-1, -2 and -3 NRC-4, -5 and -6 NRC-7, -8 and -9
Gene group GO term Number of genes GO term Number of genes GO term Number of genes
  1 Apoptosis 96 Apoptosis 83 Apoptosis 75
  2 Cell adhesion 82 Cell adhesion 87 Cell adhesion 69
  3 Cell cycle 78 Cell cycle 80 Cell cycle 97
  4 Cell motility 58 Cell motility 72 Cell motility 49
  5 Immune response 67 Immune response 46 Immune response 84
  6 Phosphorylation 89 Phosphorylation 71 Phosphorylation 65
  7 Response to 
external stimulus
80 Response to 
external stimulus
82 Response to 
external stimulus
68
  8 DnA repair 61 Cell growth 60
  9 Cell regulation 58
10 Cell assembly 69
Gene groups defined by Gene ontology (Go) term were used for generating 1 million of random gene sets (each set contains 30 genes) for finding gene signatures. nine gene signatures, defined as 
nRC (national Research Council) gene signatures, have been successfully generated from these gene groups.ARTICLE     
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when applied to another? To answer this question, we generated 
72 virtual data sets, called random microarray data sets (RDSs), by 
randomly selecting 74 samples from the Chang data set. Each RDS 
was required to maintain the same ratio of ‘good’ and ‘bad’ tumours 
as that of the original set, with  < 30% sample overlap among the 
RDSs. Next, we generated 105 distinct random gene sets (RGSs) by 
randomly selecting 30 genes from the 49 genes mentioned above. 
We performed a survival screen using each RGS against each RDS. 
For each RDS, we counted the number of gene sets (each referred to 
as a ‘passed gene set’, PGS) the survival screening P-value of which 
is  < 0.01.
Despite the fact that RDSs were subsets of the same original 
cohort, the number of PGSs varied greatly from one RDS to another 
(Fig. 1a). We extended the same analysis to the Wang data set and 
even greater variability was observed (Fig. 1b). As shown in Figure 1,   
some RDSs can have tens of thousands of PGSs, that is, gene sets 
that seem to be predictive for a particular virtual cohort. However, 
the large variability in the number of PGSs shows that one can have 
tens of thousands of PGSs for one RDS that are not transferable to 
another RDS. We conclude that most of the PGSs are not robust 
(that is, the predictive power of one PGS for one RDS can be easily 
lost in another RDS). It should be noted that all of these RDSs are 
subsets of their original data sets, which means that, in this simu-
lation study, we excluded the potential effects of variability of the 
usage of different microarray platforms and experiments performed 
by different laboratories (that is, different laboratories may have 
varied the procedures of sample handling, preparation of mRNA 
and hybridization). These results illustrate why the commonly used 
approach of using ‘one-step-clustering’ is unable to generate robust 
gene signatures. Different combinations of tumour samples in one 
data set and the extremely large individual variability of tumour 
gene expression profiles result in ‘passenger signals’ that can effec-
tively drown out the ‘real’ gene signatures in the noise.
Cancer subtypes can provide a way to improve robustness by 
providing a means of first classifying samples for which specific 
signatures can be obtained. For example, breast cancer is clinically 
divided into ER +  and ER −  subtypes17. The mixture of different sub-
types in a single breast cancer data set could confound attempts to 
identify gene signatures suitable for the entire set. To exemplify this, 
we generated six RDSs that contain only ER +  samples and another 
six RDSs that contain only ER −  samples using the Wang data set. 
We performed survival screens on these RDSs using the 105 RGSs 
mentioned above. Surprisingly, no PGSs were found in five of the six 
ER −  RDSs, whereas more than 5,000 PGSs were found in all ER +   
RDSs (Fig. 1c,d). These results suggest that we should identify spe-
cific gene signatures for ER +  and ER −  tumours separately. Other 
types of cancer might have no known subtypes. For these cases, 
we developed a method to find clinical/molecular features that are 
potentially useful for identifying subtypes as a first step for classify-
ing samples (see Supplementary Methods).
On the basis of these insights, we developed a new algorithm, 
MSS, for identifying robust and highly accurate biomarkers from 
gene expression profiles of tumours (see Supplementary Software). 
Figure 2a shows a scheme of the method (see Supplementary 
Methods).  The  algorithm  was  developed  for  searching  biomarker 
genes  with  optimized  combinatorial  effects  (that  is,  in  cases  in 
which the effect is not purely additive but combinatory and non-
linear). As a proof of concept, we applied the algorithm to breast 
cancer patients.
Gene signatures for the ER +  subtype. To apply the algorithm to 
breast cancer ER +  patients, we extracted microarray data for all the 
ER +  samples (209 samples, referred to as the training set (T1 set)) 
from the Wang data set. Genome-wide gene survival screening for 
the T1 set yielded 1,522 genes the P-values of which were  < 0.05. 
We then performed GO annotation of the 1,522 genes using cancer-
related GO terms. We generated 36 RDSs from the T1 set. For each 
selected gene group, we applied the MSS algorithm to the 36 RDSs. 
(Supplementary Tables S1 and S2 list the GO terms and parameters 
used in the analysis.)
To  assess  the  reproducibility  and  stability  of  gene  signatures 
for each selected gene group, we generated another 1 million dis-
tinct RGSs (that is, no RGS in the second set seems in the previous   
1 million RGSs) and re-ran the survival screening and gene ranking 
processes of the algorithm. Of the top 30 genes, 29 were common 
between the two independent runs for the cell cycle gene group. 
A similar reproducibility between independent runs was obtained 
for the apoptosis (28 of 30) and immune response (28 of 30) gene 
groups. However, the results from the other selected gene groups 
were not as reproducible. We therefore obtained the first batch of 
marker sets from the cell cycle, apoptosis and immune response gene 
groups, defined as National Research Council (NRC) gene signatures 
NRC-1, -2 and -3 (see Supplementary Data 1), respectively.
We applied the nearest shrunken centroid classification18 and 
the leave-one-out method (Fig. 2b, see Supplementary Methods) to 
evaluate the prognostic value of each ER +  gene signature (NRC-1, 
-2 and -3) in the T1 set and in eight other independent breast cancer 
cohorts (Supplementary Table S2). The three signatures are able to 
distinguish ‘good’ and ‘bad’ ER +  tumours in both the training and 
testing sets (Supplementary Fig. S2). In contrast, when we tested the 
top 30 genes from the non-reproducible gene lists, these lists often 
failed in the testing sets. These results highlight the robustness of the 
gene signatures generated by the MSS algorithm.
To  determine  whether  the  combined  use  of  the  three  gene   
signatures would result in a better prediction of patient outcome than 
the use of any one alone, we conducted combinatorial tests of the 
T1 set in two ways: (1) we appended the genes from the three NRC 
gene signatures to generate one meta-gene signature. The meta-
gene signature was predictive, but no better than that of the three 
independent  gene  signatures  (Supplementary  Table  S3);  and  (2)   
we used each gene signature independently and assigned 0 or 1 
(representing predicted good and poor outcomes, respectively) to 
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Figure 1 | The number of passed gene sets (PGSs) in the random data 
sets. The random microarray data sets (RDss) generated from (a) the 
Chang data set and (b) the Wang data set. The number of PGss in the six 
ER +  random data sets (c) and the six ER −  random data sets (d) generated 
from the Wang data set. A PGs is a gene set with a survival screening 
P-value of  < 0.01 when the gene set is used to perform survival screen 
analysis on an RDs. ARTICLE
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the samples. By combining the predicted results of the three gene 
signatures, we were able to stratify the samples into three groups: 
low risk (assigned 0 by all three signatures), high risk (assigned 1 by 
all three signatures) and intermediate risk (the assignments of the 
three signatures were not in agreement). Interestingly, 89 and 91% 
of the low-risk and high-risk samples, respectively, were predicted 
correctly, but only 58% of the intermediate-risk samples were pre-
dicted so.
We decided to identify more gene signatures that could be used 
to predict recurrence for the intermediate- and high-risk groups 
mentioned above. Towards this end, we re-ran the algorithm using 
the samples from intermediate- and high-risk groups of the T1 set, 
respectively.  For  the  intermediate-risk  group  samples,  we  could 
not find additional gene signatures that were significantly better to 
stratify the samples. For the high-risk group samples, however, we 
obtained another three gene signatures, defined as NRC-4, NRC-5 
and NRC-6. The parameters used for identifying these signatures 
are listed in Supplementary Table S1.
We next developed a diagnostic procedure for the ER +  samples 
using these six signatures (Fig. 2b, see Supplementary Methods). We 
validated the six signatures and the procedure in 1,182 ER +  sam-
ples from the eight independent breast cancer patient cohorts. As 
shown in Table 2 and Fig. 3, combined use of the six signatures was 
able to stratify ER +  patients into low-, intermediate- and high-risk   
groups  in  both  the  training  and  testing  sets.  In  particular,  the   
accuracy of the low-risk group reaches 87–96% in these cohorts.
Gene signatures for ER −  samples. To identify gene signatures for 
ER −  samples, we ran the same algorithms using the 77 ER −  samples 
from the Wang data set and obtained three gene signatures, NRC-7, 
NRC-8 and NRC-9. The parameters used for identifying these sig-
natures are listed in Supplementary Table S1. There are 25, 27 and 26 
genes in common, respectively, between the two independent runs 
for each gene group that was used for generating NRC-7, NRC-8 
and NRC-9. Theses results suggest that the signatures have high 
reproducibility. By combined use of the three signatures, we were 
able to stratify the ER −  samples into low-, intermediate- and high-
risk groups. Because the number of ER −  samples is usually small, 
we combined the intermediate- and high-risk groups to form the 
high-risk group. We tested the predictive performance of NRC-7, -8 
and -9 in the T1 set and in the five testing cohorts. Similar to ER +   
signatures, ER −  signatures also performed well, that is, 88–100%  
accuracy  for  low-risk  groups  in  the  testing  sets  containing  193   
samples (Table 3, Fig. 4 and Supplementary Fig. S3).
NRC signatures derived metastasis network modules. To under-
stand why these NRC signatures perform well, we examined the 
relationships between signatures and breast cancer driver-mutating 
genes, which were obtained from literature curation and the large-
scale sequencing of tumour samples, on a human protein interac-
tion  network  (see  Methods).  We  mapped  the  NRC-1  signature 
genes, which represent cell cycle processes, and the breast cancer 
driver-mutating genes onto the human protein interaction network,   
and  identified  33  breast  cancer-mutating  genes  (referred  to  as   
NRC-1_driver_genes, Fig. 5, see Supplementary Data 2), which are 
the direct interacting neighbours of NRC-1 signature genes.
Because NRC-1 is a cell cycle prognostic signature across patient 
cohorts, we hypothesized that NRC-1_driver_genes may be associ-
ated with the cell cycle process involved in cancer metastasis across 
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Figure 2 | Scheme of the algorithms. (a) multiple survival screening 
(mss). numbers in bold refer to the main steps in the mss algorithm. 
m and n represent numeric numbers. (1) Generate a survival gene list by 
a genome-wide survival analysis of the training set (T1 set). (2) Assign 
survival genes to non-exclusive Go (Gene ontology)-term-defined gene 
sets on the basis of cancer-related Go terms. (3) Generate 1 million 
random gene sets (RGss) with 30 genes taken from the Go-term-defined 
set. (4) Generate 36 random data sets (RDss) from the T1 set (maintaining 
the same ratio of ‘good’ and ‘bad’ tumours as in the original T1 set). (5)  
For each RGs–RDs pair, calculate the survival screening P-value of the RGs. 
(6) Identify the RGss that are predictive (P-value  < 0.05). The top 30 most 
frequent genes among the predictive RGss are used as a potential gene 
signature. (b) Testing the national Research Council (nRC-j, j = 1, 2, 9)  
gene signatures. A feature vector, Vi,j, based on the expression levels of 
signature genes in nRC-j is calculated for each sample i. Leave-one-out 
testing is then used to determine the ability of the gene signature to 
classify each sample. For each sample i left out, the nearest-shrunken-
centroid method is used to calculate ‘average’ feature vectors, Vi,j,g and 
Vi,j,b, for the ‘good’ or ‘bad’ tumour samples, respectively, in the remaining 
n − 1 samples. Pearson’s correlation coefficients Cor (Vi,j,g, Vi,j) and Cor 
(Vi,j,b, Vi,j) are then used to assign sample i to that group in which the 
‘average’ feature vector is more correlated to that of sample i. Details of 
the algorithms can be found in supplementary methods.ARTICLE     
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patient cohorts. To test this hypothesis, we collected all proteins 
(referred  as  NRC-1_driver_neighbor  genes)  that  are  the  direct 
interacting neighbours of not only NRC-1_driver_genes (33 genes) 
but also of cell cycle genes (using GO annotation) in which NRC-1 
signature genes have been removed. We then performed survival 
analysis of NRC-1_driver_neighbour genes in the Wang, Chang 
and Miller cohorts. Interestingly, NRC-1_driver_neighbour genes 
significantly distinguished ‘good’ and ‘bad’ ER +  tumours in all the 
cohorts. These results suggest that in the context of cell cycle proc-
esses, the 33 NRC-1_driver_genes may be associated with metas-
tasis across patient cohorts, and, furthermore, may be commonly 
used for metastasis in many ER +  samples.
We further performed the above analyses 5,000 times but randomly 
picked 33 breast cancer-mutating genes each time (see Methods)   
and showed that the 33 NRC-1_driver_genes are uniquely associ-
ated with metastasis in the context of cell cycle process (P < 0.018), 
suggesting that they are recurrently used for metastasis by many 
ER +  samples. Similar results were obtained by extending the above 
analysis to the gene signatures of NRC-2, -3 and -7- to -9 signatures 
(Fig. 5, see Supplementary Data 2). This indicates that each gene 
signature forms a network module with a unique driver-mutating 
gene set, which is used by the molecular programme of metastasis 
across many tumour samples.
Discussion
In this study, we developed the MSS algorithm using a semi-super-
vized  approach  and  identified  several  breast  cancer  prognostic 
marker sets. These marker sets were validated and shown to be 
highly predictive in eight independent breast tumour microarray 
data sets. Compared with the existing signatures, NRC signatures 
reached  both  high  predictive  accuracies  (87–96%,  88–100%  for 
ER +  and ER −  patients, respectively) and high robustness (tested 
in eight independent breast cancer cohorts containing 1,182 ER +   
and 193 ER −  samples). Network analyses of these signatures and 
of breast cancer driver-mutating genes identified several network 
modules involved in metastasis.
Using a stimulation study, we showed that the predictive power 
of most of the gene signatures in one data set can be easily lost in 
another  data  set,  suggesting  that  interpatient  and  intratumour 
heterogeneity has an important role in affecting the robustness of 
gene signatures. These insights indicate that the dominantly used 
concept/approach of ‘one-step-clustering’ of gene expression pro-
files is unable to generate robust gene signatures. This motivated 
Table 2 | The accuracy of ER +  samples by combinatorial use of the NRC signatures.
Data sets Number of samples Low-risk group (%)* Intermediate-risk group (%)† High-risk group (%)‡
GsE2034 (Wang cohort) 209 89.4 60.9 90.9
Chang cohort 173 93.7 82.3 57.1
GsE3494 (miller cohort) 205 87.0 74.1 57.5
GsE11121 156 90.9 79.5 47.8
GsE1456 131 93.4 69.1 39.3
GsE9195 77 94.3 78.1 0.0
GsE6532 250 88.7 79.8 45.0
GsE7378 54 96.4 87.5 50.0
GsE12093 136 90.3 82.5 17.7
metadata 1,009 90.2 79.8 36.6
*Percentage of actual ‘good’ samples in the predicted low-risk group.
†Percentage of actual ‘good’ samples in the predicted intermediate-risk group.
‡Percentage of actual ‘bad’ samples in the predicted high-risk group. Chang cohort contains samples from van ‘t Veer cohort, which was used for training (see methods). We tested 173 samples in 
Chang cohort after excluding the samples from van ‘t Veer cohort. Chang cohort consists of cDnA arrays, while others are Affymetrix arrays. metadata contain 1,009 ER +  samples from Affymetrix 
data sets excluding the training set, Wang cohort. Data sets are represented by nCBI GEo (http:/ /www.ncbi.nlm.nih.gov/geo/) IDs.
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Figure 3 | Kaplan–Meier curves of the risk groups for ER +  patients with 
10-year disease-free survival predicted by the combinatorial use of 
NRC-1 to NRC-6. (a) Wang cohort. (b) Chang cohort. (c) miller cohort. 
(d) metadata containing 1,009 ER +  samples from Affymetrix data sets 
minus the training set (Wang cohort). Green, blue and dark orange curves 
represent low-, intermediate- and high-risk groups, respectively. P-values 
were obtained from the χ2-test. 
Table 3 | The accuracy of ER −  samples by combinatorial use 
of the NRC signatures.
Data sets
Number of 
samples
Low-risk group 
(%)*
High-risk group 
(%)†
GsE2034 
(Wang cohort)
77 100.0 54.0
Chang cohort 47 90.9 51.4
GsE3494 
(miller cohort)
31 100.0 35.3
GsE11121 44 87.5 69.2
GsE1456 28 100.0 47.8
GsE6532 43 89.5 62.5
metadata 146 90.9 51.9
*Percentage of actual ‘good’ in predicted low-risk group.
†Percentage of actual ‘bad’ samples in the predicted high-risk group. Chang cohort contains 
samples from van ‘t Veer cohort, which was used for training (see methods). We tested 47 
samples in Chang cohort after excluding the samples from van ‘t Veer cohort. Chang cohort 
consists of cDnA arrays, while others are Affymetrix arrays. metadata contain 146 ER −  
samples from Affymetrix data sets excluding the training set, Wang cohort. Data sets are 
represented by nCBI GEo (http:/ /www.ncbi.nlm.nih.gov/geo/) IDs.ARTICLE
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the development of the MSS algorithm. The heart of MSS is the 
screening of randomized data sets using randomly generated gene 
combinations. The interactions of gene expression values within one 
predictive gene set are known to be nonlinear. Thus, the algorithm 
is preferable to simple clustering methods for identifying predic-
tive gene signatures. Furthermore, the reproducibility and stability 
of gene signatures were evaluated and confirmed by performing 
another round of screening of multiple data sets and gene ranking. 
The results are encouraging and can be interpreted to mean that a 
core set of genes within a predictive gene signature preferentially 
interact with each other and are commonly used in the metastatic 
programme by many individual tumours.
Data overfitting is always a challenge in biomarker discovery. 
There  is  a  large  input  dimensionality  (thousands  of  genes)  and   
a paucity of patient samples (a few hundred is typical); thus, it is 
statistically  plausible  to  have  small  subsets  that  are  randomly   
correlated with any given desired outcome, irrespective of any bio-
logical functionality of the gene expression itself. As we mentioned 
earlier, there are many more ‘passenger signals’ in gene expression 
profiles than expected. Thus, the ‘cancer driver-associated signals’ 
are deeply buried in passenger signals. To cope with this problem, 
we targeted select genes in a biased manner, that is, by selecting those 
cancer-associated (cancer hallmark) genes the expression values of 
which are correlated with patient survival. By doing so, we mini-
mized sparse correlations and the problem of overfitting. Genes in 
one cancer hallmark GO term may be expressed in a coordinated 
manner so that a subset of these genes could maintain the interac-
tions of their expressions. Therefore, gene signatures derived from 
these GO terms most likely reflect cancer processes and are there-
fore more robust. Finally, to improve accuracy, we used the results 
of three predictive gene signatures combinatorially and showed that 
this strategy is able to significantly increase the predictive accuracy, 
especially in low-risk groups.
Tumour progression and metastasis are distinct processes. Onco-
genic transformation leading to tumour progression is not sufficient 
for metastatic competence. It is believed that many genetic and epi-
genetic events contribute to the metastatic path. Tumour genome 
sequencing provides a powerful approach for cataloguing cancer 
driver-mutating genes; however, it cannot distinguish those genes 
that are the drivers of tumour progression, metastasis or both. In 
this study, we have dissected several sets of driver-mutating genes 
for metastasis by integrative analysis of the human protein interac-
tion network and prognostic signatures.
NRC driver-gene sets show that most of these mutated genes are 
significantly enriched for signalling proteins (P-values range from 
3.5×10 − 5 to 4.9×10 − 11), whereas more than 40% of genes in the NRC 
signatures encode secreted and cell surface proteins (Supplementary 
Data 1). These results suggest that each network module contains 
two parts: a set of NRC signature genes (that is, the ‘modulated part’; 
these genes are dynamically modulated between ‘good’ and ‘bad’ 
tumours) and a unique set of cancer driver-mutating genes (that is, 
the ‘mutating part’; one or more genes are mutated and hijack normal 
cell signalling events) that are the direct protein interacting part-
ners of the signature genes. Taken together, we believe that, during   
metastasis, one or more genes of the ‘mutating part’ get mutated and 
alter normal cell signalling, whereas the genes of the ‘modulated 
part’ are dynamically modulated between ‘good’ and ‘bad’ tumours. 
Thereafter, the genes from the ‘mutating part’ are rewired (that is, 
the interaction between the proteins from the two parts is changed 
because of the high or low expression of genes). More importantly, 
the enrichment of secreted and cell surface proteins in the ‘mutating 
part’ suggests an intensive communication between network mod-
ules and tumour microenvironments. This conclusion supports the 
notion that the nature of the metastatic process is such that cancer 
cells need to communicate with the tumour microenvironment and 
overcome hurdles for cell motility, circulation and the infiltration of 
distant organs. The mediators of metastasis (that is, the ‘mutating 
part’ of the network modules) may also have dual functions that 
provide both a local advantage for malignant progression in the pri-
mary tumour and a distal advantage for metastasis. Recently, p53 
was shown to have both functions19.
For the ER +  and ER −  subtypes, we have identified three meta-
stasis network modules representing three different cell signalling 
processes,  suggesting  that  a  higher  order  of  coordination  exists 
between these cellular processes. Indeed, many interacting links can 
be found among the genes of the three processes/network modules 
(that is, cell cycle, apoptosis and immunological responses for the 
ER +  subtype, and apoptosis, cell proliferation and cell adhesion 
for the ER −  subtype). Furthermore, the fact that NRC signatures 
have predictive power across patient cohorts suggests that these net-
work modules are collaborated and repeatedly used in many breast 
tumour samples by the molecular programme of metastasis.
In addition, the metastasis driver gene sets of apoptosis often contain 
many genes in common with those representing other key metastasis 
signalling processes. This observation is in agreement with the finding 
that, during evolution, apoptotic proteins tend to integrate into other 
signalling pathways20. By examining the GO terms of NRC signatures 
for the ER +  and ER −  subtypes, we found that only one GO term or 
gene group (apoptosis) is common between the two subtypes (NRC-3 
for ER +  and NRC-7 for ER − ). However, the gene sets of the two apop-
totic groups have only a single gene in common, and the network mod-
ules are also different between the two subtypes. These results suggest 
that different molecular metastatic programmes are used in the ER +   
and ER −  subtypes, respectively.
In summary, we showed that the concept of ‘one-step-clustering’ 
of gene expression profiles, which has been dominantly used in the 
past decade, is not suitable for generating robust gene signatures. 
Therefore, we developed an algorithm for identifying prognostic 
markers that can be used in combination to stratify breast cancer 
patients into groups with different risk ranks. The NRC signature 
sets showed high predictive accuracy, especially for low-risk patient 
groups. More importantly, the algorithm can be applied to other 
cancer types and subtypes. Our approach might provide a framework 
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Figure 4 | Kaplan–Meier curves of the risk groups for ER −  patients 
with a 10-year disease-free survival predicted by the combinatorial 
use of NRC-7 to NRC-9. (a) Wang cohort. (b) Chang cohort. (c) miller 
cohort. (d) metadata containing 146 ER −  samples from Affymetrix data 
sets minus the training set (Wang cohort). Green and dark orange curves 
represent low- and high-risk groups, respectively. P-values were obtained 
using the χ2-test. ARTICLE     
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for discovering robust and reproducible gene signatures for specific 
phenotypes, such as clinical outcome, drug response or other dis-
ease features. Finally, a network analysis of NRC gene signatures 
and breast cancer driver-mutating genes identified several network 
modules that are recurrently used in breast tumours by the molecu-
lar programme of metastasis. Each network module contains a core 
set of driver-mutating genes, the mutation of which alters cell sig-
nalling, and another set of genes of one NRC signature the expres-
sions of which change dynamically, rewiring the mutating genes (for 
cell signalling) and being extensively involved in cell communica-
tions between tumours and their microenvironments.
Methods
Breast cancer data sets. The breast cancer microarray data sets used were from 
Wang et al.15 (Wang cohort or data set, Affymetrix arrays), Chang et al.6 (Chang 
cohort or data set, cDNA arrays), van ‘t Veer et al.5 (van ‘t Veer cohort or data 
set, cDNA arrays), Miller et al.21 (Miller cohort or data set, Affymetrix arrays) 
and from several other Affymetrix array data sets with the following NCBI GEO 
(http://www.ncbi.nlm.nih.gov/geo/) IDs: GSE11121, GSE1456, GSE6532, GSE9151, 
GSE7378 and GSE12093. Supplementary Table S2 summarizes the number of ER +  
and ER −  samples for each data set. The Wang data set and the van ‘t Veer cohort 
were used as the T1 set (we tested whether adding an extra data set, the van ‘t Veer 
cohort, to RDSs generated from the Wang cohort could improve the performance 
of MSS; we did not observe significant improvements), whereas other cohorts were 
used as the testing sets. The Chang cohort contains samples from the van ‘t Veer 
cohort. When testing the Chang cohort, we removed the samples in common with 
the van ‘t Veer cohort. Samples without clinical information were dropped and the 
gene expression data were z-score normalized.
Human protein interaction network. The data for constructing the human pro-
tein interaction network were downloaded from the I2D database22.
Breast cancer driver-mutating genes. Breast cancer driver-mutating genes were 
obtained from COSMIC (Catalogue Of Somatic Mutations In Cancer, http://www.
sanger.ac.uk/genetics/CGP/cosmic/) and Sjoblom et al.23
Microarray metadata normalization. Except for the Chang and van ‘t Veer data 
sets, the data sets used are Affymetrix arrays. We combined a metadata set for all 
ER +  samples from the testing sets generated using Affymetrix platforms. To do so, 
Affymetrix expression data were analysed using the MAS5.0 algorithm. Subse-
quently, data were log2 transformed, the values of the probes belonging to the same 
gene were averaged and then median-centred across arrays. Finally, gene expres-
sion data were z-score normalized across arrays. A similar procedure was applied 
to generate a metadata set for ER −  samples.
Survival analysis of NRC_driver_neighbour genes. We use NRC-1_driver_genes 
to illustrate this analysis. NRC-1_driver_genes are the breast cancer driver-mutat-
ing genes that are also direct interacting partners of NRC-1 signature genes. We 
identified 33 NRC-1_driver_genes. To perform survival analysis, we collected all 
proteins (referred to as NRC-1_driver_neighbour genes) from the protein interac-
tion network that are direct interacting neighbours of the NRC-1_driver_genes and 
also members of the cell cycle gene set from which the NRC-1 signature genes were 
removed. We tested the predictive power of NRC-1_driver_neighbour genes in the 
Wang, Chang and Miller data sets.
To do so, we first performed t-tests of the expression values of each  
NRC-1_driver_neighbour gene between the ‘good’ and ‘bad’ tumours of the ER +  
samples of the three cohorts. To increase the number of cell cycle genes of the 
NRC-1_driver_neighbour genes for the survival analysis, we selected those genes 
the P-values of which are  < 0.5 and 0.2 (we used these two cutoffs and found  
that the trends were the same regardless of the cutoffs) to perform the survival 
analysis for the ER +  samples of each cohort. We then obtained P-values for the 
NRC-1_driver_neighbour genes Pc-1-NRC1, Pc-2-NRC1 and Pc-3-NRC1 for each cohort.
The same method was applied to NRC-2, -3, -7, -8 and -9 gene signatures.  
For NRC-7, -8 and -9, the ER −  samples of the three cohorts were used.
Randomization tests for the driver_neighbour genes. We use the 33 NRC-
1_driver_genes to illustrate the test. To perform the randomization tests, we 
randomly selected 33 breast cancer driver-mutating genes that were mapped onto 
the protein interaction network. Using the survival analysis method mentioned 
above, we selected the 33-driver_neighbour genes and performed the survival 
analysis in the ER +  samples of the three cohorts (the training and two testing sets: 
Chang and Miller data sets) and obtained P-values, Pc-1-random, Pc-2-random and Pc-3-random, 
for each cohort, respectively. We tested the null hypothesis, Pc-1-random >  = Pc-1-NRC1, 
Figure 5 | Relationships between NRC signature genes and their driver-mutating genes in the protein interaction network. (a) For nRC-1, -2 and -3. 
(b) For nRC-7, -8 and -9. The largest spheres represent the common driver_genes from all the driver_gene sets, whereas the middle and small sizes of 
spheres represent driver_genes and signature genes, respectively. A driver_gene is a gene that is known as a breast cancer driver_mutating gene and the 
coding protein of which directly interacts with the protein coded by a signature gene. A common driver_gene or a common signature gene is a gene that 
is found in at least two driver_gene lists (that is, nRC-1 driver_genes and nRC-2 driver_genes) or in at least two signature gene lists (that is, nRC-1 and 
nRC-2), respectively. ARTICLE
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Pc-2-random >  = Pc-2-NRC1 and Pc-3-random >  = Pc-3-NRC1, by performing 5,000 randomization 
tests and calculating the P-value. 
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